A2A Pharmaceuticals
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
180 Varick St, New York, New York, 10014...Website
www.a2apharma.comRevenue
<$5 MillionIndustry
About A2A Pharmaceuticals
A2A Pharmaceuticals is a clinical stage oncology company focused on leveraging artificial intelligence and proprietary computational systems to develop novel drug alternatives for life-threatening diseases, including cancer and muscular dystrophy. Their lead asset, AO-252, is currently in Phase 1 clinical trials targeting ovarian, triple negative, and endometrial cancers, showing promising tumor reduction results. The company aims to expand its research into additional cancer types and has established partnerships with larger pharmaceutical companies for collaborative projects. A2A Pharmaceuticals is dedicated to advancing drug design and discovery through innovative technology and strategic collaborations.Explore more
A2A Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to A2A Pharmaceuticals
Compare insights from companies similar to A2A Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
A2A Pharmaceuticals
<$5M
11-50
Private
-
2016
EP
Edward PainterFounder & Chairman & Chief Operating Officer
A2A Pharmaceuticals Tech Stack
A closer look at the technologies used by A2A Pharmaceuticals
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding A2A Pharmaceuticals
Sign Up For FreeTo access detailed company insights
A2A Pharmaceuticals is a clinical stage oncology company focused on leveraging artificial intelligence and proprietary computational systems to develop novel drug alternatives for life-threatening diseases, including cancer and muscular dystrophy. Their lead asset, AO-252, is currently in Phase 1 clinical trials targeting ovarian, triple negative,... Read More
